Kardos Peter, de Zeeuw Justus, Trompetter Inga, Braun Simon, Ilieva Yuliya
Lung Centre Maingau, 60316 Frankfurt am Main, Germany.
Pneumologische Praxis, 51105 Köln, Germany.
Pharmaceuticals (Basel). 2025 May 20;18(5):754. doi: 10.3390/ph18050754.
: The combination therapy for acute bronchitis with several plant extracts, such as Ivy and Thyme or Primrose and Thyme, is assumed to offer added benefit over single extract preparations. However, no clinical trials have yet demonstrated such a therapeutic advantage. : In this three-arm, open-label, randomized clinical trial, patients with acute bronchitis were assigned to groups receiving Ivy extract EA 575 (Prospan Cough Drops), Ivy/Thyme extract combination (Bronchipret Drops), or Thyme/Primrose extract combination (Bronchicum Drops) according to their respective labels. The primary endpoint was the assessment of non-inferiority, and the second endpoint was the assessment of superiority of Ivy vs. each of the two comparators (Ivy/Thyme and Thyme/Primrose) regarding the change in Bronchitis Severity Score between baseline and day 7. In total, 325 adult patients were considered for evaluation. : Non-inferiority of Ivy extract was statistically significant against both comparators (both < 0.0001). Superiority of Ivy extract was statistically significant against Ivy/Thyme extract ( < 0.0001) but missed statistical significance against Thyme/Primrose extract ( < 0.0607). The incidence of adverse events was low and comparable between the groups. All adverse events were non-serious. : these data revealed that Ivy extract EA 575 is non-inferior in acute bronchitis treatment compared to both comparators and superior to Ivy/Thyme.
:采用几种植物提取物联合治疗急性支气管炎,如常春藤和百里香提取物组合或报春花和百里香提取物组合,被认为比单一提取物制剂更具优势。然而,尚无临床试验证明这种治疗优势。:在这项三臂、开放标签、随机临床试验中,急性支气管炎患者根据各自的标签被分配到接受常春藤提取物EA 575(Prospan止咳糖)、常春藤/百里香提取物组合(Bronchipret滴剂)或百里香/报春花提取物组合(Bronchicum滴剂)的组中。主要终点是评估非劣效性,次要终点是评估常春藤提取物与两个对照物(常春藤/百里香和百里香/报春花)相比,在基线至第7天期间支气管炎严重程度评分变化方面的优越性。总共325名成年患者被纳入评估。:常春藤提取物相对于两个对照物均具有统计学意义上的非劣效性(均P<0.0001)。常春藤提取物相对于常春藤/百里香提取物具有统计学意义上的优越性(P<0.0001),但相对于百里香/报春花提取物未达到统计学意义(P<0.0607)。不良事件发生率较低,且各组之间相当。所有不良事件均不严重。:这些数据表明,在急性支气管炎治疗中,常春藤提取物EA 575与两个对照物相比非劣效,且优于常春藤/百里香提取物。